2
Participants
Start Date
October 31, 2014
Primary Completion Date
November 30, 2017
Study Completion Date
November 30, 2017
NY-ESO-1 T cells
cyclophosphamide
cyclophosphamide 60mg/kg/day day -7 and day -6
Fludarabine
Fludarabine given 25mg/m2 day -5 to day -1
Interleukin 2
Interleukin 2 (IL2) immunotherapy given day 0 to day 6
The Christie NHS Foundation Trust, Manchester
Collaborators (1)
The Christie NHS Foundation Trust
OTHER
Erasmus Medical Center
OTHER
Ospedale San Raffaele
OTHER
University College London Hospitals
OTHER
Karolinska University Hospital
OTHER
The Netherlands Cancer Institute
OTHER
Fiona Thistlethwaite
OTHER